Bacteria have existed for billions of years and have constantly evolved to survive. Now, some have learned to resist even our most powerful antibiotics. Antimicrobial resistance (AMR) is already here and, according to the World Health Organization, it’s directly responsible for 1.3 million deaths every year. The theme for this year’s World Antimicrobial Awareness Week is “Act Now: Protect Our Present, Secure Our Future.” Watch the video below to find out how we are advancing antibiotic R&D at Roche to protect patients and help prevent a larger crisis tomorrow👇. Join the conversation during #AMR Week. Learn more 👉🔗 https://spkl.io/6044Ajhjr #AntimicrobialResistance #RocheAMR #WAAW
Yes, Antimicrobial resistance is one of the most complex and pressing global health challenges of our time. I truly appreciate Roche’s continuous commitment to advancing antibiotic R&D and protecting patients through scientific innovation. As a healthcare professional deeply interested in driving meaningful impact in this field, the mission of tackling AMR resonates strongly with me. Thank you for raising awareness during AMR Week and for leading efforts that safeguard both our present and our future.
We need to see better prescribing from doctors
A critical reminder of the growing global threat of antimicrobial resistance. Advancing antibiotic R&D is essential to protecting patients today and preventing even greater health challenges in the future. Important work from Roche during AMR Awareness Week.
Antimicrobial resistance is accelerating at a crisis pace—bacteria are evolving much faster than our ability to develop new antibiotics, placing millions of people at risk each year. The World Health Organization now estimates that AMR is directly responsible for 1.3 million deaths annually, with projections rising to over 1.9 million direct deaths and 8.2 million associated deaths by 2050. Roche’s commitment to advancing antibiotic R&D is both timely and urgent. Without decisive action in drug development, stewardship, and global collaboration, AMR threatens not only current patients but also the future of modern medicine. World Antimicrobial Awareness Week’s message—“Act Now: Protect Our Present, Secure Our Future”—is a critical call to prioritize innovation and collective responsibility before drug-resistant infections spiral further out of control. Novel antibiotics, rapid diagnostics, and robust surveillance are essential tools, but lasting impact will come from sustained scientific investment, policy action, and public awareness—making AMR Week a rallying point for change at every level.
This is a powerful reminder of how urgently antibiotic innovation needs to evolve and keep evolving. AMR isn’t a future threat, it’s already today’s reality. Seeing Roche invest in new mechanisms, precision approaches and R&D models gives hope for patients. I’m glad to see this topic brought forward with clarity during AMR Week.
What’s striking about AMR is that it isn’t just a scientific problem, it’s a systems problem. Bacteria evolve faster than our policies, our diagnostics, and sometimes even our care pathways. R&D is critical, but so is the role of patient groups, clinicians, and communities in shaping responsible use and accelerating early detection. This is exactly the kind of challenge that requires everyone at the table.
A timely reminder of the scale and urgency of antimicrobial resistance. The WHO’s estimate of 1.3 million deaths annually underscores why AMR is not a distant threat but a present crisis. Highlighting this during World Antimicrobial Awareness Week helps reinforce the need for collective action across research, policy, and patient care. Roche’s focus on advancing antibiotic R&D is encouraging, particularly when framed in terms of both immediate patient protection and long-term preparedness. This dual emphasis on resilience and responsibility is exactly what our field needs to sustain trust and impact. Looking forward to seeing how these efforts contribute to broader alliances in safeguarding global health.
AMR is already reshaping infectious disease risk. Roche’s spotlight on evolving resistance aligns innovation with urgency. Acting now means rethinking stewardship, accelerating R&D, and protecting the utility of last-line agents before they’re rendered ineffective.
AMR is unfortunately becoming even worse with private prescribing in some cases.
Certified AGILE Leader 🔹Strategic Vision - Realised
2dHuge THANK YOU to all the colleagues involved in driving this important work and bringing such powerful content to life. Your dedication to advancing antibiotic innovation and raising awareness around AMR makes a difference. Emmanuelle Cottreel, Ken Bradley Séverine Louvel Grateful to be part of the Roche Team where we are committed to protecting patients today and securing a safer future for all. 👏